HealthcareNAICS 446110
Sell a Independent Pharmacies business
Healthcare services M&A has been the busiest sector by deal count for four straight years. the specialty revenue is highly recurring and durable.
What moves the multiple
Value drivers in independent pharmacies
Healthcare businesses sit within a broad multiple band. These are the specific factors that determine where you land inside it.
Independent Pharmacies-specific
Independent pharmacies with specialty-pharmacy accreditation (URAC, ACHC) or compounding capability trade at meaningful premium — the specialty revenue is highly recurring and durable.
Payer mix (commercial vs government) — commercial-weighted practices command premium
Provider retention post-close (employment agreements + earn-outs standard)
Multiple providers/practitioners (not solo-owner-dependent)
Modern EHR + billing infrastructure
Ancillary revenue lines (imaging, PT, aesthetics, labs)

Diligence risks
What buyers scrutinize
Every category has structural risks that buyers double-click on. Preparing responses in advance keeps them out of the purchase-price adjustment column.
Independent Pharmacies-specific risk
Retail pharmacy margins have been squeezed by PBM reimbursement pressure and DIR fees; buyers apply substantial discounts for high-percentage retail-prescription revenue.
Payer reimbursement rate compression
Physician recruiting difficulty
State-specific corporate practice of medicine (CPOM) restrictions
Stark Law and anti-kickback compliance exposure
Active buyers
Who buys independent pharmacies businesses
Buyer archetype depends on scale. Sub-$1M SDE draws individuals and search funds. $1–3M SDE opens platform and strategic interest. $3M+ EBITDA is full LMM buyer territory.
Physician-services PE platform
PE PlatformCategory-specific platforms (Dental Care Alliance, US Dermatology, US Physical Therapy, US Oral Surgery, US Eye) are the primary bidders on $1.5M+ EBITDA practices.
Health system / MSO
StrategicRegional hospital systems and management services organizations (MSOs) absorb strategic practices at moderate multiples with faster closes.
Physician successor
IndividualSolo/small-group succession to a rising practitioner remains common below the PE threshold ($700K-$1.5M EBITDA).
Playbook
Exit playbook — healthcare
The single largest driver of purchase-price outcome is preparation depth. These are the levers that move the needle in healthcare exits.
- 1
Recruit a second provider before going to market
18-24 months pre-saleSolo-provider practices trade at 30-40% discount to multi-provider peers. Adding a second before sale is often the highest ROI move.
- 2
Move to a modern integrated EHR + billing system
18-24 months pre-saleLegacy systems trigger diligence discounts. Migrations take 6-12 months to stabilize; start early.
- 3
Optimize payer mix and reduce Medicaid concentration
12-24 months pre-saleCommercial-weighted practices command premium multiples. Realistic mix shift takes 12+ months.
- 4
Engage healthcare M&A counsel early — this segment has unique diligence
6-9 months pre-saleCPOM, Stark, anti-kickback, and state-specific licensing overlays require specialist counsel. Standard M&A attorneys under-serve healthcare.

Topical cluster
Related industries
Owners of independent pharmacies businesses often also operate — or acquire — businesses in adjacent verticals.
Medical Supply Distribution
SDE 3x–5x · EBITDA 6.5x–10x
Durable Medical Equipment (DME)
SDE 2.8x–4.5x · EBITDA 6x–9.5x
Medical Laboratories
SDE 2.5x–4.5x · EBITDA 7x–11x
Veterinary Practices
SDE 2.3x–4x · EBITDA 8x–14x
Primary Care Practices
SDE 1.8x–3.2x · EBITDA 6x–10x
Addiction Treatment Centers
SDE 2.5x–4.5x · EBITDA 6.5x–10.5x
FAQ
Independent Pharmacies exits, answered
What is a independent pharmacies business worth?
Who buys independent pharmacies businesses right now?
What drives multiple expansion in independent pharmacies?
What are the biggest risks in selling a independent pharmacies business?
What revenue range makes independent pharmacies sellable to a professional buyer?
How long does it take to sell a independent pharmacies business?
Data provenance: Valuation multiples anchored in PitchBook Healthcare Services 2025 + Bass Berry LMM Healthcare Report. Buyer names and platforms are cited from public M&A disclosures, SEC filings, and press releases. Nothing on this page is fabricated. Multiples are whole-market ranges — your specific business will price above or below based on the drivers and risks above.
Published March 17, 2025 · Updated August 2, 2026
Ready to explore an exit?
Get matched to a independent pharmacies specialist.
Answer three quick questions. We surface vetted brokers with real independent pharmacies deal experience.